NOVT
Neutral signalScored 2026-09-16 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Novanta Inc.
- Nom
- Novanta Inc.
- Secteur
- Technology
- Industrie
- Hardware, Equipment & Parts
- Bourse
- NASDAQ
- Capitalisation
- $5.7B
- Employés
- 3,000
- PDG
- Matthijs Glastra
- Site web
- https://www.novanta.com
- Marché
- CGNXCOHRFNIPGPLPTHMKSI
Operating globally, Novanta Inc. and its affiliated companies specialize in the development, production, and distribution of advanced photonics, vision, and precision motion components and sub-assemblies. These highly engineered solutions are supplied to Original Equipment Manufacturers (OEMs) across the medical and industrial sectors. Within its Photonics division, Novanta provides a suite of laser-driven technologies. These encompass systems for laser scanning, beam manipulation, and various laser types such as CO2, solid-state, ultrafast, and optical light engines. Their applications span critical areas like industrial manufacturing, precision measurement (metrology), advanced imaging in healthcare and biological research, DNA sequencing, and specialized medical laser treatments. The Vision segment delivers an array of medical-grade innovations. This portfolio comprises instruments like medical insufflators, pumps, and their associated consumables, alongside comprehensive visualization tools. It also features wireless communication systems, video recording devices, and integration platforms designed for operating theaters. Further offerings include optical data acquisition, machine vision systems, radio frequency identification (RFID) solutions, thermal recording devices, spectrometry equipment, and integrated touchscreen displays. Furthermore, the Precision Motion division specializes in supplying components such as optical and inductive encoders, high-precision motors, servo drives, and complete motion control systems. This segment also delivers integrated stepper motors, sophisticated robotic end-effectors, air bearings, and air bearing spindles. Novanta distributes its extensive product lines through various channels, including its dedicated direct sales team, value-added resellers, distribution partners, and system integrators. These offerings are available under well-known brand names such as Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind. Founded in 1968, the company operated as GSI Group, Inc. until its rebranding to Novanta Inc. in May 2016. Its corporate headquarters are located in Bedford, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 663 titres (~97 858,80 $ US)
- Insiders
- Secor Thomas N
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$97,859
Avg sell (VWAP, 90d window) $147.60 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$97,859 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-11
- Last synced
-
2026-09-17 09:54:31
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-11 | Secor Thomas N | Sell · S S · 10b5-1 | 663 | $147.60 | ≈ $97,859 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-18 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-11-13 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-08-04 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-07-22 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2022-07-25 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2019-10-22 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-08-01 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-05-22 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-04-17 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-04-15 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-09-16 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
NOVT presents a paradoxical profile: exceptional liquidity (score 90) provides a strong balance sheet buffer, but deteriorating profitability trends and a collapsing ROIC signal deep operational headwinds that liquidity…
The first sentence of the analysis written for NOVT on 2026-09-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $98K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $98K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 3.69 · operating margin 12%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 41.6% | 44.4% | 45.4% | 44.0% | 42.5% | |
| Ebit Margin | 9.3% | 13.1% | 14.0% | 12.5% | 11.6% | |
| Ebitda Margin | 15.6% | 18.9% | 19.3% | 18.7% | 17.8% | |
| Operating Profit Margin | 11.9% | 11.6% | 12.5% | 12.0% | 9.1% | |
| Pretax Profit Margin | 7.1% | 8.3% | 9.5% | 10.1% | 7.9% | |
| Continuous Operations Profit Margin | 5.5% | 6.8% | 8.3% | 8.6% | 7.1% | |
| Net Profit Margin | 5.5% | 6.8% | 8.3% | 8.6% | 7.1% | |
| Bottom Line Profit Margin | 5.5% | 6.8% | 8.3% | 8.6% | 7.1% | |
| Current Ratio | 3.685 | 2.584 | 2.984 | 2.556 | 2.032 | |
| Quick Ratio | 2.799 | 1.723 | 1.911 | 1.535 | 1.349 | |
| Solvency Ratio | 0.235 | 0.186 | 0.216 | 0.192 | 0.133 | |
| Cash Ratio | 1.793 | 0.679 | 0.755 | 0.608 | 0.638 | |
| Price To Earnings Ratio | 80.946 | 85.826 | 82.961 | 65.322 | 124.176 | |
| Price To Earnings Growth Ratio | -4.648 | -6.969 | -34.512 | 1.405 | 10.514 | |
| Forward Price To Earnings Growth Ratio | -4.648 | -6.969 | -34.512 | 1.405 | 10.514 | |
| Price To Earnings Diluted Ratio | 80.946 | 86.311 | 83.371 | 65.956 | 125.057 | |
| Price To Earnings Diluted Growth Ratio | -4.776 | -6.974 | -42.936 | 1.431 | 9.770 | |
| Price To Book Ratio | 3.313 | 7.365 | 8.963 | 8.387 | 11.973 | |
| Price To Sales Ratio | 4.440 | 5.786 | 6.847 | 5.627 | 8.831 | |
| Price To Free Cash Flow Ratio | 89.899 | 38.854 | 60.296 | 68.095 | 86.149 | |
| Price To Operating Cash Flow Ratio | 67.967 | 34.648 | 50.273 | 53.361 | 65.959 | |
| Debt To Assets Ratio | 0.189 | 0.339 | 0.330 | 0.394 | 0.402 | |
| Debt To Equity Ratio | 0.260 | 0.632 | 0.601 | 0.847 | 0.946 | |
| Debt To Capital Ratio | 0.206 | 0.387 | 0.375 | 0.459 | 0.486 | |
| Long Term Debt To Capital Ratio | 0.161 | 0.356 | 0.342 | 0.427 | 0.452 | |
| Financial Leverage Ratio | 1.375 | 1.862 | 1.821 | 2.149 | 2.355 | |
| Working Capital Turnover Ratio | 2.346 | 3.503 | 3.314 | 3.862 | 3.722 | |
| Operating Cash Flow Ratio | 0.302 | 0.945 | 0.863 | 0.552 | 0.514 | |
| Operating Cash Flow Sales Ratio | 0.065 | 0.167 | 0.136 | 0.105 | 0.134 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.756 | 0.892 | 0.834 | 0.784 | 0.766 | |
| Debt Service Coverage Ratio | 1.948 | 3.522 | 4.007 | 5.108 | 5.859 | |
| Interest Coverage Ratio | 5.433 | 3.512 | 4.280 | 6.601 | 8.671 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.308 | 10.341 | 8.654 | 6.846 | 7.262 | |
| Operating Cash Flow Coverage Ratio | 0.188 | 0.337 | 0.297 | 0.185 | 0.192 | |
| Capital Expenditure Coverage Ratio | 4.099 | 9.236 | 6.015 | 4.621 | 4.267 | |
| Dividend Paid And Capex Coverage Ratio | 4.099 | 9.236 | 6.015 | 4.621 | 4.267 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 28.191 | 32.521 | 37.288 | 32.582 | 52.742 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 41.6% | ▼-2.8% | ▼-2.0% |
| Ebit Margin | 9.3% | ▼-3.8% | ▼-2.8% |
| Ebitda Margin | 15.6% | ▼-3.3% | ▼-2.4% |
| Operating Profit Margin | 11.9% | ▲0.2% | ▲0.5% |
| Pretax Profit Margin | 7.1% | ▼-1.2% | ▼-1.5% |
| Continuous Operations Profit Margin | 5.5% | ▼-1.3% | ▼-1.8% |
| Net Profit Margin | 5.5% | ▼-1.3% | ▼-1.8% |
| Bottom Line Profit Margin | 5.5% | ▼-1.3% | ▼-1.8% |
| Current Ratio | 3.685 | ▲1.101 | ▲0.917 |
| Quick Ratio | 2.799 | ▲1.076 | ▲0.935 |
| Solvency Ratio | 0.235 | ▲0.049 | ▲0.043 |
| Cash Ratio | 1.794 | ▲1.114 | ▲0.899 |
| Price To Earnings Ratio | 80.946 | ▼-4.880 | ▼-6.901 |
| Price To Earnings Growth Ratio | -4.648 | ▲2.321 | ▲2.194 |
| Forward Price To Earnings Growth Ratio | -4.648 | ▲2.321 | ▲2.194 |
| Price To Earnings Diluted Ratio | 80.946 | ▼-5.365 | ▼-7.383 |
| Price To Earnings Diluted Growth Ratio | -4.776 | ▲2.198 | ▲3.921 |
| Price To Book Ratio | 3.313 | ▼-4.052 | ▼-4.688 |
| Price To Sales Ratio | 4.440 | ▼-1.346 | ▼-1.866 |
| Price To Free Cash Flow Ratio | 89.899 | ▲51.045 | ▲21.240 |
| Price To Operating Cash Flow Ratio | 67.968 | ▲33.320 | ▲13.526 |
| Debt To Assets Ratio | 0.189 | ▼-0.150 | ▼-0.142 |
| Debt To Equity Ratio | 0.260 | ▼-0.372 | ▼-0.397 |
| Debt To Capital Ratio | 0.206 | ▼-0.181 | ▼-0.176 |
| Long Term Debt To Capital Ratio | 0.161 | ▼-0.195 | ▼-0.187 |
| Financial Leverage Ratio | 1.375 | ▼-0.487 | ▼-0.537 |
| Working Capital Turnover Ratio | 2.346 | ▼-1.157 | ▼-1.003 |
| Operating Cash Flow Ratio | 0.302 | ▼-0.643 | ▼-0.333 |
| Operating Cash Flow Sales Ratio | 0.065 | ▼-0.102 | ▼-0.056 |
| Free Cash Flow Operating Cash Flow Ratio | 0.756 | ▼-0.136 | ▼-0.050 |
| Debt Service Coverage Ratio | 1.948 | ▼-1.574 | ▼-2.141 |
| Interest Coverage Ratio | 5.433 | ▲1.921 | ▼-0.266 |
| Short Term Operating Cash Flow Coverage Ratio | 1.308 | ▼-9.033 | ▼-5.574 |
| Operating Cash Flow Coverage Ratio | 0.188 | ▼-0.149 | ▼-0.052 |
| Capital Expenditure Coverage Ratio | 4.099 | ▼-5.137 | ▼-1.549 |
| Dividend Paid And Capex Coverage Ratio | 4.099 | ▼-5.137 | ▼-1.549 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 28.191 | ▼-4.330 | ▼-8.474 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $4.35B | $5.49B | $6.04B | $4.84B | $6.24B | |
| Enterprise value | $4.31B | $5.85B | $6.34B | $5.23B | $6.62B | |
| EV / Sales | 4.40x | 6.16x | 7.19x | 6.08x | 9.36x | |
| EV / Op. cash flow | 67.36x | 36.90x | 52.77x | 57.65x | 69.93x | |
| EV / Free cash flow | 89.09x | 41.38x | 63.29x | 73.57x | 91.34x | |
| EV / EBITDA | 28.19x | 32.52x | 37.29x | 32.58x | 52.74x | |
| Net debt / EBITDA | -0.26x | 1.99x | 1.76x | 2.42x | 3.00x | |
| Current ratio | 3.69x | 2.58x | 2.98x | 2.56x | 2.03x | |
| Income quality | 1.19x | 2.47x | 1.65x | 1.23x | 1.88x | |
| Graham number | $34 | $29 | $29 | $28 | $22 | |
| Graham net-net | $3 | -$10 | -$7 | -$11 | -$12 | |
| Tax burden | 77.3% | 81.1% | 87.0% | 85.0% | 89.6% | |
| Interest burden | 76.4% | 63.6% | 67.9% | 81.1% | 68.4% | |
| Working capital | $570.2M | $265.9M | $276.1M | $256.0M | $189.9M | |
| Invested capital | $1.56B | $1.19B | $1.05B | $1.06B | $1.03B | |
| Return on assets | 3.0% | 4.6% | 5.9% | 6.0% | 4.1% | |
| Operating ROA | 7.3% | 8.5% | 9.0% | 8.3% | 6.1% | |
| Return on tangible assets | 5.5% | 10.4% | 12.2% | 12.6% | 9.5% | |
| Return on equity | 4.1% | 8.6% | 10.8% | 12.8% | 9.7% | |
| Return on invested capital | 5.5% | 7.3% | 8.7% | 8.0% | 5.4% | |
| Return on capital employed | 7.3% | 9.1% | 10.2% | 9.6% | 6.1% | |
| Earnings yield | 1.2% | 1.2% | 1.2% | 1.5% | 0.8% | |
| Free cash flow yield | 1.1% | 2.6% | 1.7% | 1.5% | 1.2% | |
| Capex / Op. cash flow | 24.4% | 10.8% | 16.6% | 21.6% | 23.4% | |
| Capex / Depreciation | 25.2% | 30.9% | 42.8% | 37.0% | 51.1% | |
| Capex / Sales | 1.6% | 1.8% | 2.3% | 2.3% | 3.1% | |
| SG&A / Sales | 20.0% | 18.5% | 18.7% | 18.5% | 18.3% | |
| R&D / Sales | 9.7% | 10.1% | 10.4% | 10.0% | 10.3% | |
| Stock comp / Sales | 3.0% | 2.5% | 2.9% | 2.7% | 3.6% | |
| Intangibles / Total assets | 45.8% | 55.5% | 51.3% | 52.7% | 57.0% | |
| Days sales outstanding | 69d | 58d | 58d | 58d | 60d | |
| Days payables outstanding | 60d | 53d | 43d | 57d | 62d | |
| Operating cycle | 189d | 158d | 171d | 185d | 173d | |
| Cash conversion cycle | 128d | 105d | 128d | 129d | 111d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-16 How to Build a Humanoid Body Last month we broke down the three key areas needed to build your own humanoid. We have already looked at the companies behind the technologies required to build a humanoid''s brain.
- 2026-09-04 Are Robots the New Normal? Bet on these ETFs to Invest in the Future Robotics is entering a new era as AI fuels humanoid adoption, with four ETFs offering diversified exposure to the sector''s growth.
- 2026-09-01 Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Novanta Inc. $NOVT Connor Clark and Lunn Investment Management Ltd. acquired a new position in Novanta Inc. (NASDAQ: NOVT) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,845 shares of the technology company''s stock, valued at approximately $786,000. Several other large investors have
- 2026-08-28 Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026 BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical a.
- 2026-08-18 Recent Price Trend in Novanta (NOVT) is Your Friend, Here''s Why If you are looking for stocks that are well positioned to maintain their recent uptrend, Novanta (NOVT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 2026-08-12 Are You Looking for a Top Momentum Pick? Why Novanta (NOVT) is a Great Choice Does Novanta (NOVT) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-08-12 Novanta Inc. $NOVT Shares Bought by Bank of America Corp DE Bank of America Corp DE increased its stake in Novanta Inc. (NASDAQ: NOVT) by 18.3% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 456,241 shares of the technology company''s stock after acquiring an additional 70,728 shares during the
- 2026-08-07 Amundi Purchases 3,516 Shares of Novanta Inc. $NOVT Amundi increased its position in shares of Novanta Inc. (NASDAQ: NOVT) by 17.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,187 shares of the technology company''s stock after buying an additional 3,516 shares during the quarter. Amundi owned 0.07% of
- 2026-08-07 Novanta Q2 Earnings Call Highlights Novanta (NASDAQ: NOVT) reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition. Chair and Chief Executive Officer Matthijs Glastra said reported revenue grew 10% year over year during the quarter, while adjusted EBITDA increased 16%
- 2026-08-07 Novanta Q2 Earnings Call Highlights Novanta NASDAQ: NOVT reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition.